Tag Archives: iLet

Novo Reduces Semaglutide WAC Prices; Pfizer To Commercialize Ecnoglutide in China; Novo Ph2 GGG data; AbbVie Builds Out Obesity Manufacturing; Fortress Sells PRV; Alveus Closes $197M Series A; Beta Bionics FDA Warning Letter; Hims & Hers Q4 ’25 Earnings

A series of cardiometabolic-related news items has been observed from Novo Nordisk, Sciwind Biosciences/Pfizer, AbbVie, Fortress Biotech, Alveus Therapeutics, Beta Bionics, and Hims & Hers. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Register

Already a member? Log in here

Beta Bionics Investor Event at ADA 2025

Beta Bionics (BB) hosted an investor event and associated webcast at ADA 2025 (view slides). As seen by FENIX, in-room attendance was convincingly robust. Below, FENIX provides a summary and insights from the event, including BB’s new patch pump named “Mint.”

This content is for Read Less members only.
Register

Already a member? Log in here

Beta Bionics Management Changes Ahead of Insulin-only iLet Bionic Pancreas Launch; Glooko Partners with Johns Hopkins

Two cardiometabolic-related news items have been observed: Beta Bionics recently announced executive leadership and board transitions ahead of launching its insulin-only iLet bionic pancreas; and Glooko announced a collaboration with Johns Hopkins HealthCare Solutions to helps patients with their diabetes management. Below, FENIX provides highlights and insights for the respective new items.

This content is for Read Less members only.
Register

Already a member? Log in here